Ruxolitinib (a specific JAK1/JAK2 inhibitor) was highlighted here based on its use in current phase 1, 2, and 3 clinical trials against pancreatic cancer (trials NCT01423604, NCT02117479, NCT02119663, and NCT01822756). Here, JAK1 is linked to familial pancreatic carcinoma.